Silexan in anxiety disorders: Clinical data and pharmacological background

The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
Siegfried KasperA Dienel

Abstract

Silexan is a lavender oil preparation available in 80-mg capsules. Here we review clinical trials investigating its anxiolytic efficacy, safety and tolerability in humans, as well as preclinical investigations supporting this therapeutic use. Besides three selected publications reporting preclinical investigations, seven clinical trials are included, of which five had a treatment duration of 6 or 10 weeks. Primary outcome measure was the HAM-A total score reduction, while single items were assessed with regard to effects on concomitant depressive symptoms and on quality of sleep. In patients with subthreshold (subsyndromal) anxiety or generalised anxiety disorder (GAD), an anxiolytic effect of Silexan was evident after 2 weeks. HAM-A total score reductions between baseline and end of treatment were significantly superior to placebo in patients with subthreshold anxiety and comparable with those achieved under lorazepam or paroxetine in patients with GAD. In addition, Silexan had beneficial effects on typical concomitant symptoms of anxiety disorders, such as impaired sleep, somatic complaints, co-morbid depression or decreased quality of life. Except for mild gastrointestinal symptoms, Silexan did not induce any adverse effects...Continue Reading

References

Oct 26, 1999·The British Journal of Psychiatry : the Journal of Mental Science·H A PincusL E McQueen
Jan 6, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M H Lader
May 15, 2002·Advances in Therapy·Lut Tamam, Nurgul Ozpoyraz
Apr 22, 2004·Psychological Medicine·Peter M LewinsohnDaniel N Klein
Jun 17, 2005·The New England Journal of Medicine·Ronald C KesslerAlan M Zaslavsky
Dec 20, 2005·The International Journal of Neuropsychopharmacology·David S BaldwinMalcolm Lader
Mar 7, 2007·Annals of Internal Medicine·Kurt KroenkeBernd Löwe
Dec 25, 2007·Gender Medicine·Marrie H J Bekker, Janneke van Mens-Verhulst
Jul 16, 2008·Journal of Clinical Psychopharmacology·Karl RickelsGeorge W Case
Dec 8, 2009·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·H Woelk, S Schläfke
Jun 10, 2010·Journal of Psychopharmacology·N J KalkA R Lingford-Hughes
Jun 22, 2011·Neurochemistry International·Laura MusazziMaurizio Popoli
Sep 8, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·H U WittchenH-C Steinhausen
Dec 5, 2012·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Leo B SilenieksGuy A Higgins
Jan 31, 2013·Wiener medizinische Wochenschrift·Vikas Kumar
Feb 13, 2013·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Oxana DoroshyenkoUwe Fuhr
Jan 25, 2014·The International Journal of Neuropsychopharmacology·Siegfried KasperAngelika Dienel
Aug 22, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Siegfried KasperAngelika Dienel
Jan 1, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Siegfried KasperSandra Schläfke
Mar 21, 2017·International Journal of Psychiatry in Clinical Practice·M GastparS Kasper

❮ Previous
Next ❯

Citations

Jan 27, 2019·European Archives of Psychiatry and Clinical Neuroscience·Kenji Hashimoto
Dec 15, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Yulu ZhangWei Peng
Dec 11, 2020·The International Journal of Neuropsychopharmacology·Erich SeifritzSiegfried Kasper
May 24, 2019·Journal of Psychiatric Research·Erich SeifritzEdith Holsboer-Trachsler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.